Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 2:00 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Relatives Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Norethindrone/Ethinyl Estradiol 0.4 mg/35 Mcg Chewable Tablets Under Non-Fasted Conditions

NCT01344369
View directory record Official record
Conditions
Healthy
Interventions
Norethindrone/Ethinyl Estradiol, FEMCON® Fe
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 29, 2011 · Synced Sep 6, 2026, 2:00 PM EDT
Completed Phase 1 Interventional

Bioequivalence Study of Azacitidine for Injection in Myelodysplastic Syndrome (MDS) Patients

NCT01152346
View directory record Official record
Conditions
Myelodysplastic Syndrome
Interventions
Azacitidine for Injection, Vidaza®
Drug
Lead sponsor
Bioniche Pharma USA LLC
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
4
States / cities
Anaheim, California • Corona, California • Fresno, California + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2015 · Synced Sep 6, 2026, 2:00 PM EDT
Completed Not applicable Interventional Results available

Study Evaluating the Timing of Intrauterine Insemination in Relation to Positive Home Ovulation Prediction Kit

NCT02294773
View directory record Official record
Conditions
Infertility
Interventions
Intrauterine Insemination, Clomiphene, Letrozole
Procedure · Drug
Lead sponsor
Midwest Fertility Specialists
Industry
Eligibility
21 Years to 39 Years · Female only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
2
States / cities
Fort Wayne, Indiana • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 8, 2015 · Synced Sep 6, 2026, 2:00 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Randomized Controlled Trial Comparing Acellular Collagen Biomesh (Pelvisoft) to Polypropylene Mesh(Pelvitex) for Sacral Colpopexy

NCT00564083
View directory record Official record
Conditions
Uterine Prolapse
Interventions
sacral colpopexy
Procedure
Lead sponsor
Atlantic Health System
Other
Eligibility
18 Years and older · Female only
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2010
U.S. locations
1
States / cities
Morristown, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 21, 2011 · Synced Sep 6, 2026, 2:00 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Relative Bioavailability Study of Glyburide/Metformin HCl 5 mg/500 mg Tablets Under Fasting Conditions

NCT00865436
View directory record Official record
Conditions
Healthy
Interventions
Glyburide and Metformin Hydrochloride Tablets 5 mg/500 mg, CLUCOVANCE® 5 mg/500 mg Tablets, single dose
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Aug 16, 2010 · Synced Sep 6, 2026, 2:00 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Bioavailability, Safety, and Pharmacodynamics of Dexlansoprazole Delayed-Release Orally Disintegrating Tablets in Healthy Participants

NCT02064907
View directory record Official record
Conditions
Bioavailability
Interventions
Dexlansoprazole Delayed Release Orally Disintegrating Tablets, Dexlansoprazole Delayed Release Capsules
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 13, 2015 · Synced Sep 6, 2026, 2:00 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Compare the Blood Levels of Sildenafil Following Administration of an Experimental Tablet vs. the Conventional Oral Tablet in Healthy Subjects

NCT00866463
View directory record Official record
Conditions
Erectile Dysfunction
Interventions
Sildenafil
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 31, 2021 · Synced Sep 6, 2026, 2:00 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A 5-Period, Single Dose, Phase 1 Study in Healthy Elderly Subjects to Assess Relative Bioavailability and Food Effect of Two Oral Formulations of GSK1325756 (Free Base vs HBr Salt) and Food Effect on the HBr Formulation When Given With Omeprazole

NCT02453022
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Danirixin HBr 50 mg IR Tablet, Danirixin FB 50 mg IR Tablet, Prilosec (omeprazole) 40mg Delayed-Release capsule
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
65 Years to 80 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 23, 2018 · Synced Sep 6, 2026, 2:00 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Relative Potency of Multiple Oral Doses of LUM001 and SHP626 in Overweight and Obese Adults as Assessed by Fecal Bile Acid Excretion

NCT02475317
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Placebo, Maralixibat, Volixibat
Drug
Lead sponsor
Mirum Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 3, 2019 · Synced Sep 6, 2026, 2:00 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

STUDY OF PF-06882961 IN PARTICIPANTS WITH AND WITHOUT VARYING DEGREES OF HEPATIC IMPAIREMENT

NCT04604496
View directory record Official record
Conditions
Hepatic Impairment, Healthy Volunteers
Interventions
PF-06882961 20MG
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Mar 20, 2024 · Synced Sep 6, 2026, 2:00 PM EDT
Active, not recruiting No phase listed Observational

Vagus Nerve Response in Gastroparesis Patients

NCT04207996
View directory record Official record
Conditions
Gastroparesis
Interventions
Not listed
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Sep 6, 2026, 2:00 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Two-part Study to Compare a Tablet and Capsule Formulation of GSK2838232 With and Without Food, and to Assess the Safety and Drug Levels of Repeated Once-daily Doses of GSK2838232 Without Ritonavir

NCT03234036
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus, HIV Infections
Interventions
GSK2838232 100 mg tablet, GSK2838232 50 mg capsule, Ritonavir 100 mg tablets, Placebo for GSK2838232 tablets
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 27, 2020 · Synced Sep 6, 2026, 2:00 PM EDT
Active, not recruiting Not applicable Interventional

Feasibility of the 5-Step Method in the U.S.

NCT06565429
View directory record Official record
Conditions
Family Members, Relatives, Substance-Related Disorders, Alcohol-Related Disorders, Coping Skills, Stress, Psychological, Stress Physiology
Interventions
5-Step Method Intervention
Behavioral
Lead sponsor
Villanova University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Winchester, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Sep 6, 2026, 2:00 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Relative Bioavailability of 2 Fixed Dose Combinations of Linagliptin/Metformin Compared With Single Tablets

NCT01845077
View directory record Official record
Conditions
Healthy
Interventions
2x500 mg Metformin (Glumetza), 5 mg Linagliptin/1000 mg Metformin FDC, 5 mg Linagliptin (Tradjenta), 3x500 mg Metformin (Glumetza), 2 x 500 mg Metformin (Glumetza), 5 mg Linagliptin/1000mg Metformin FDC, 2 x 2.5 mg Linagliptin/750 mg Metformin FDC
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 50 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 18, 2014 · Synced Sep 6, 2026, 2:00 PM EDT
Completed Phase 3 Interventional Results available

Trial to Confirm the Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in T1DM Children

NCT03667053
View directory record Official record
Conditions
Hypoglycemia
Interventions
dasiglucagon, placebo, GlucaGen HypoKit
Drug
Lead sponsor
Zealand Pharma
Industry
Eligibility
6 Years to 17 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
3
States / cities
Escondido, California • New Haven, Connecticut • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 29, 2021 · Synced Sep 6, 2026, 2:00 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluate Severe Hepatic Impairment on Dacomitinib PK

NCT03865446
View directory record Official record
Conditions
Severe Hepatic Impairment
Interventions
Dacomitinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Nov 5, 2020 · Synced Sep 6, 2026, 2:00 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

90 mg Fluoxetine Hydrochloride Capsules Under Fasting Conditions

NCT01247272
View directory record Official record
Conditions
Healthy
Interventions
Fluoxetine Hydrochloride, PROZAC WEEKLY®
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Feb 20, 2011 · Synced Sep 6, 2026, 2:00 PM EDT
Completed Phase 2 Interventional

A Study to Demonstrate That Anti-HIV Drug Therapy Can be Stopped Without Causing Viral Resistance, and to Characterize Drug Elimination From the Body

NCT00029341
View directory record Official record
Conditions
HIV Infections
Interventions
Treatment Interruption
Behavioral
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
7
States / cities
San Francisco, California • Denver, Colorado • Cincinnati, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2008 · Synced Sep 6, 2026, 2:00 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single/Multiple Dose Bioavailability Trial

NCT00751556
View directory record Official record
Conditions
Healthy
Interventions
Naproxen Sodium 660mg, Commercial Aleve 220 mg
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Apr 20, 2014 · Synced Sep 6, 2026, 2:00 PM EDT
Completed Phase 3 Interventional Results available

A Study to Examine the Effect of Levodopa-Carbidopa Intestinal Gel (LCIG) Therapy Relative to That of Optimized Medical Treatment (OMT) on Non-motor Symptoms (NMS) Associated With Advanced Parkinson's Disease (PD)

NCT02549092
View directory record Official record
Conditions
Advanced Parkinson's Disease
Interventions
Optimized Medical Treatment, Levodopa-Carbidopa Intestinal Gel, Nasojejunal (NJ) tube, Percutaneous endoscopic gastrostomy with a jejunal (PEG-J) tube
Drug · Device
Lead sponsor
AbbVie
Industry
Eligibility
30 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
8
States / cities
Fountain Valley, California • Boca Raton, Florida • Jacksonville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2023 · Synced Sep 6, 2026, 2:00 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Clarithromycin 500 mg Tablets Under Non-Fasting Conditions

NCT00836706
View directory record Official record
Conditions
Healthy
Interventions
clarithromycin, BIAXIN®
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002
U.S. locations
1
States / cities
East Grand Forks, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 19, 2024 · Synced Sep 6, 2026, 2:00 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Tobacco Product Susceptibility and Substitutability by Rurality and Alcohol Use

NCT07010601
View directory record Official record
Conditions
Alcohol Use, E-cigarette Use, Cigarette Use
Interventions
Experimental Tobacco Marketplace, Hypothetical Novel Nicotine Product Purchase Tasks
Behavioral
Lead sponsor
Mark J Rzeszutek, PhD
Other
Eligibility
21 Years and older
Enrollment
737 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Sep 22, 2025 · Synced Sep 6, 2026, 2:00 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Fed Bioavailability Study of Zonisamide Capsules

NCT00687167
View directory record Official record
Conditions
Healthy
Interventions
Zonisamide 100 mg Capsule, Zonisamide (Zonegran®) 100 mg Capsule
Drug
Lead sponsor
Mutual Pharmaceutical Company, Inc.
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Jan 25, 2010 · Synced Sep 6, 2026, 2:00 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Mother-Baby Study - Relative Reinforcing Value (RRV)

NCT06072651
View directory record Official record
Conditions
Eating Behavior
Interventions
Relative Reinforcing Value of Food
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
0 Days and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 6, 2025 · Synced Sep 6, 2026, 2:00 PM EDT